https://scholars.lib.ntu.edu.tw/handle/123456789/544053
標題: | Population-based case-control study of chinese herbal products containing aristolochic acid and urinary tract cancer risk | 作者: | Lai M.-N. SHUO-MENG WANG PAU-CHUNG CHEN Chen Y.-Y. Wang J.-D. |
公開日期: | 2010 | 卷: | 102 | 期: | 3 | 起(迄)頁: | 179-186 | 來源出版物: | Journal of the National Cancer Institute | 摘要: | Background: Consumption of Chinese herbs that contain aristolochic acid (eg, Mu Tong) has been associated with an increased risk of urinary tract cancer. Methods: We conducted a population-based case-control study in Taiwan to examine the association between prescribed Chinese herbal products that contain aristolochic acid and urinary tract cancer. All patients newly diagnosed with urinary tract cancer (case subjects) from January 1, 2001, to December 31, 2002, and a random sample of the entire insured population from January 1, 1997, to December 31, 2002 (control subjects), were selected from the National Health Insurance reimbursement database. Subjects who were ever prescribed more than 500 pills of nonsteroidal anti-inflammatory drugs and/or acetaminophen were excluded, leaving 4594 case patients and 174701 control subjects in the final analysis. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were estimated by using multivariable logistic regression models for the association between prescribed Chinese herbs containing aristolochic acid and the occurrence of urinary tract cancer. Models were adjusted for age, sex, residence in a township where black foot disease was endemic (an indicator of chronic arsenic exposure from drinking water [a risk factor for urinary tract cancer]), and history of chronic urinary tract infection. Statistical tests were two-sided. Results: Having been prescribed more than 60 g of Mu Tong and an estimated consumption of more than 150 mg of aristolochic acid were independently associated with an increased risk for urinary tract cancer in multivariable analyses (Mu Tong: at 61-100 g, OR = 1.6, 95% CI = 1.3 to 2.1, and at >200 g, OR = 2.1, 95% CI = 1.3 to 3.4; aristolochic acid: at 151-250 mg, OR = 1.4, 95% CI = 1.1 to 1.8, and at >500 mg, OR = 2.0, 95% CI = 1.4 to 2.9). A statistically significant linear dose-response relationship was observed between the prescribed dose of Mu Tong or the estimated cumulative dose of aristolochic acid and the risk of urinary tract cancer (P <. 001 for both). Conclusions: Consumption of aristolochic acid-containing Chinese herbal products is associated with an increased risk of cancer of the urinary tract in a dose-dependent manner that is independent of arsenic exposure. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-76349101626&doi=10.1093%2fjnci%2fdjp467&partnerID=40&md5=f10cd4065dbba4a11e91ead46278a8f7 https://scholars.lib.ntu.edu.tw/handle/123456789/544053 |
ISSN: | 0027-8874 | DOI: | 10.1093/jnci/djp467 | SDG/關鍵字: | aristolochic acid; herbaceous agent; adult; aged; Aristolochia fangchi; Aristolochia manshuriensis; article; Asarum heterotropoides; cancer risk; Caulis Aristolochiae; controlled study; demography; dose response; drug exposure; drug industry; drug synthesis; drug use; female; Fructus Aristolochiae; groups by age; herbal medicine; human; major clinical study; male; medicinal plant; multivariate logistic regression analysis; population based case control study; prescription; priority journal; Radix Aristolochiae; risk assessment; risk factor; sex difference; Taiwan; urinary tract cancer; urinary tract infection; Adult; Aged; Aristolochic Acids; Carcinogens; Case-Control Studies; Confounding Factors (Epidemiology); Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Female; Humans; Logistic Models; Male; Middle Aged; Odds Ratio; Research Design; Risk Factors; Taiwan; Urologic Neoplasms |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。